| 產(chǎn)品編號(hào) | BIO0217SM |
| 英文名稱 | Anti-human LAG3 / CD223 (Relatlimab Biosimilar) |
| 中文名稱 | |
| 抗體來(lái)源 | |
| 克隆類型 | Monoclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human,Cynomolgus |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.58 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | Human IgG4SP |
| 純化方法 | Protein A |
| 保存條件 | For long term storage, the produce should be stored at -20°C or lower. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Relatlimab inhibited the tumor growth of MC38 on Human LAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 53.8% at 10 mpk at D28.
Human LAG3 CHO cells were stained with Anti-LAG3 / CD223 Reference Antibody (relatlimab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.5464 ug/mL.
Immobilized human LAG3 His at 2 ug/mL can bind Anti-LAG3 / CD223 Reference Antibody (relatlimab), EC50=0.02812 ug/mL.
The purity of Anti-LAG3 / CD223 Reference Antibody (relatlimab) is 100%, determined by SEC-HPLC.
Anti-LAG3 / CD223 Reference Antibody (relatlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
